{
  "docId": "019de075-e430-7299-a96e-811e562ad763",
  "docSlug": "dd1cc6bfd53a92cef2d40347c5bc25e6",
  "documentTitle": "Alkermes | Results Presentation Deck | 27 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 27,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide illustrates the escalation of doses for both SAD and MAD study arms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e430-7299-a96e-811e562ad763/15",
  "deckHref": "/decks/019de075-e430-7299-a96e-811e562ad763",
  "deckJsonHref": "/decks/019de075-e430-7299-a96e-811e562ad763.json",
  "deckAnchorHref": "/decks/019de075-e430-7299-a96e-811e562ad763#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "SAD and MAD dose escalation steps",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee779ece-d46d-4a73-88ad-0d9393ee2fdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "list",
      "text": "Each dose cohort in both SAD and MAD included 8 new participants (6 on ALKS 2680, 2 on placebo). Objectives: Safety and tolerability, Pharmacokinetics (PK) and pharmacodynamics (PD).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa9b2c61-3573-4ff6-ae4b-ee2c3adba18e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "*Denotes dynamic decision points for triggering subsequent cohorts. aIn MAD, participants were dosed for 10 days once daily.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4932f076-e53a-498f-a1fc-28bfdea879fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Ongoing Randomized, Double-Blind, Placebo-Controlled First-in-Human Study of ALKS 2680: SAD and MAD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee89642b-775e-4833-926a-adc27cade05b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 13,
      "beatId": "a2d3f125-9d63-41e7-ad4b-d97f1d4906af",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The preliminary results from a Phase 1 study of ALKS 2680 demonstrate potential for growth",
      "position": 2,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}